Top Markets
Coin of the day
EQRx, Inc. EQRx, Inc.

EQRx, Inc.

EQRX
Peringkat dalam Saham #11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Harga Saham
$2.34
Terakhir disinkronkan: 2023-11-09
Kapitalisasi Pasar
$728.90M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan EQRx, Inc. (EQRX)

Kategori

Riwayat hasil dividen untuk EQRx, Inc. (EQRX)
Hasil dividen (TTM) dari EQRx, Inc. (simbol saham: EQRX) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk EQRx, Inc. (EQRX) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
Perusahaan Hasil Dividen Negara
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH